KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

You can use the following database to type the name of a prescription drug to track changes in the average price pharmacies pay for it. Click on a drug name to see its lowest, highest and latest ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

The companies raised prices a median 4%, though some drugs will cost thousands of dollars more.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...